Attovia Therapeutics CFO ownership unchanged

The Chief Financial Officer’s two options cover 215,285 and 80,731 underlying common shares, with separate exercise prices and expiration dates.

Rhea-AI Filing Summary

Attovia Therapeutics, Inc. (ATTO) amended and replaced Steven Chan’s Form 3 filed August 4, 2026, reporting no change to his beneficial ownership. Chan, the Chief Financial Officer, directly holds options for 215,285 common shares at $3.5302, expiring November 13, 2034, and 80,731 shares at $4.9237, expiring May 17, 2035. For the first and second options, respectively, 25% of the underlying shares vested on October 14, 2025, and May 18, 2026; each provides for an additional 1/48th to vest monthly over three years, subject to continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Chan Steven

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) F1	--	--	--
holding	Stock Option (Right to Buy) F2	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 296,016 contracts (Direct)

Footnotes (2)

1. F1. The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on October 14, 2025, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.
2. F2. The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on May 18, 2026, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.

Key Figures

Shares underlying first direct stock option: 215,285 shares Exercise price of first direct stock option: $3.5302 per share Shares underlying second direct stock option: 80,731 shares +1 more

4 metrics

Shares underlying first direct stock option 215,285 shares Expiration date: November 13, 2034

Exercise price of first direct stock option $3.5302 per share Option expires November 13, 2034

Shares underlying second direct stock option 80,731 shares Expiration date: May 17, 2035

Exercise price of second direct stock option $4.9237 per share Option expires May 17, 2035

Key Terms

Stock Option (Right to Buy), beneficial ownership, vesting schedule, continued service

4 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

beneficial ownership financial

"beneficial ownership of the Issuer's securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

vesting schedule financial

"The vesting schedule is as follows"

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

continued service financial

"subject to continued service to the Issuer through such date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ATTO stock options does CFO Steven Chan report?

Steven Chan reports two directly held options: one covering 215,285 common shares at $3.5302, expiring November 13, 2034, and one covering 80,731 shares at $4.9237, expiring May 17, 2035. The amendment reports no change in his beneficial ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/08/2026 - 07:57 PM EDT Accepted by SEC EDGAR 10/08/2026 - 07:56 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Chan Steven

(Last) (First) (Middle)

C/O ATTOVIA THERAPEUTICS, INC.

1091 INDUSTRIAL ROAD, SUITE 310

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/04/2026

3. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)
08/04/2026

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	11/13/2034	Common Stock	215,285	$3.5302	D
Stock Option (Right to Buy)	(2)	05/17/2035	Common Stock	80,731	$4.9237	D

Explanation of Responses:

1. The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on October 14, 2025, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.

2. The option vests over a four-year period. The vesting schedule is as follows: 25% of the shares of common stock underlying the stock option vested on May 18, 2026, and an additional 1/48th of the total shares underlying the stock option vest in equal monthly installments over three years, subject to continued service to the Issuer through such date.

Remarks:

This Form 3 amendment amends the Form 3 filed on August 4, 2026, which reported the Reporting Person's beneficial ownership using the Issuer's CIK number. This Form 3 amendment has been filed under the Reporting Person's CIK and reflects him as the Reporting Person. This filing amends and replaces the original filing in its entirety. No changes have been made or are being reported with respect to the Reporting Person's beneficial ownership of the Issuer's securities.

	/s/ Steven Chan	10/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)